Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: A review

Abstract

Dalbavancin is a parenteral lipoglycopeptide antibiotic derived from teicoplanin, an analog of vancomycin. It is mainly used for skin and soft tissue infections. The sustained half-life of around 14 days makes dalbavancin a novel option for potential use as sequential treatment in infections like infective endocarditis, which require prolonged antibiotic courses. However, only a few studies have been reported in the literature and its use remains limited. We reviewed the currently available literature using dalbavancin in the treatment of infective endocarditis due to Gram-positive organisms. Almost all patients received dalbavancin as sequential therapy following standard of care antibiotics. The overall clinical efficacy was around 90% and it appeared to be well tolerated.